Biotech Growth Trust (The) (LSE:BIOG) Cyclically Adjusted Revenue per Share: £0.96 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BIOG Biotech Growth Trust (The) PLC LSE:BIOG
37 GF Score
Price £16.10
! 2 Warning Signs
View Full Analysis

What is Biotech Growth Trust (The) Cyclically Adjusted Revenue per Share?

Biotech Growth Trust (The) LSE:BIOG +0.12% 37 Cyclically Adjusted Revenue per Share is £0.96 as of Mar. 2026. GuruFocus rates LSE:BIOG with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biotech Growth Trust (The)'s adjusted revenue per share data for the fiscal year that ended in Mar. 2026 was £5.735. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is £0.96 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biotech Growth Trust (The)'s average Cyclically Adjusted Revenue Growth Rate was 966.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -21.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biotech Growth Trust (The) was 23.90% per year. The lowest was -53.10% per year. And the median was 6.00% per year.

As of today (2026-07-23), Biotech Growth Trust (The)'s current stock price is £ 16.10. Biotech Growth Trust (The)'s Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar. 2026 was £0.96. Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio of today is 16.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotech Growth Trust (The) was 142.78. The lowest was 6.44. And the median was 11.31.


Biotech Growth Trust (The)  (LSE:BIOG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.10/0.96
=16.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotech Growth Trust (The) was 142.78. The lowest was 6.44. And the median was 11.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biotech Growth Trust (The) Cyclically Adjusted Revenue per Share Related Terms


Biotech Growth Trust (The) Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biotech Growth Trust (The)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotech Growth Trust (The) Cyclically Adjusted Revenue per Share Chart

Biotech Growth Trust (The) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.70 0.77 0.09 0.96

Biotech Growth Trust (The) Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.00 0.09 0.00 0.96

LSE:BIOG vs BLK, BX, KKR: Cyclically Adjusted Revenue per Share Comparison

For the Asset Management subindustry, Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Growth Trust (The) Cyclically Adjusted PS Ratio vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotech Growth Trust (The)'s Cyclically Adjusted PS Ratio falls into.


LSE:BIOG
37GF Score
Biotech Growth Trust (The) PLC LSE:BIOG
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotech Growth Trust (The) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotech Growth Trust (The)'s adjusted Revenue per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.735/140.8000*140.8000
=5.735

Current CPI (Mar. 2026) = 140.8000.

Biotech Growth Trust (The) Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 1.753 102.700 2.403
201803 -0.493 105.100 -0.660
201903 0.436 107.000 0.574
202003 1.415 108.600 1.835
202103 5.545 109.700 7.117
202203 -5.060 116.500 -6.115
202303 -0.935 126.800 -1.038
202403 2.164 131.600 2.315
202503 -2.501 136.100 -2.587
202603 5.735 140.800 5.735

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of £0.96 mean?
Biotech Growth Trust (The) (LSE:BIOG) has a Cyclically Adjusted Revenue per Share of £0.96 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotech Growth Trust (The) and its competitors.
Is Biotech Growth Trust (The)'s Cyclically Adjusted Revenue per Share too high?
Biotech Growth Trust (The)'s current Cyclically Adjusted Revenue per Share is £0.96. Overall, Biotech Growth Trust (The) has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Biotech Growth Trust (The)'s Cyclically Adjusted Revenue per Share compare to BLK and BX?
Biotech Growth Trust (The)'s Cyclically Adjusted Revenue per Share of £0.96 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for an Asset Management company?
A good Cyclically Adjusted Revenue per Share depends on the Asset Management industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biotech Growth Trust (The) and its competitors. Biotech Growth Trust (The)'s current Cyclically Adjusted Revenue per Share is £0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotech Growth Trust (The) stock overvalued right now?
Biotech Growth Trust (The) (LSE:BIOG) has a current Cyclically Adjusted Revenue per Share of £0.96. The current Cyclically Adjusted Revenue per Share is £0.96. Biotech Growth Trust (The)'s overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biotech Growth Trust (The) (LSE:BIOG), the current Cyclically Adjusted Revenue per Share is £0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotech Growth Trust (The) Business Description

Address 25 Southampton Buildings, London, GBR, WC2A 1AL
Biotech Growth Trust (The) PLC is an externally managed investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world.
37GF Score

Get the complete analysis for LSE:BIOG

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£16.10
Price